- Home
- SKT vs GPCR Comparison
SKT vs GPCR Comparison
Compare SKT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKT | GPCR |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SKT | GPCR |
|---|---|---|
| Price | $37.40 | $21.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $40.20 | ★ $107.29 |
| AVG Volume (30 Days) | 913.0K | ★ 1.0M |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $69.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.13 | $20.50 |
| 52 Week High | $42.53 | $94.90 |
Technical Indicators
Market Signals| Indicator | SKT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 26.25 |
| Support Level | $34.97 | $20.73 |
| Resistance Level | $37.61 | $57.15 |
| Average True Range (ATR) | 0.61 | 1.15 |
| MACD | 0.26 | 0.66 |
| Stochastic Oscillator | 97.85 | 30.63 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.